Hematology-Oncology
Latest news
316 articles · 20 / page
Epcoritamab Monotherapy Demonstrates Potent Antitumor Activity in Richter Transformation: Insights from EPCORE CLL-1
The EPCORE CLL-1 trial evaluated epcoritamab, a CD3×CD20 bispecific antibody, in patients with Richter transformation. While the 47.6% overall response rate narrowly missed the 50% target, the results highlight a significant therapeutic sig
Intravenous Iron Outperforms Oral Prophylaxis in Non-Anaemic Iron-Deficient Pregnancy: A Paradigm Shift in Antenatal Care?
This multicentre RCT found that intravenous iron significantly boosts maternal hemoglobin before delivery in non-anaemic iron-deficient women compared to standard oral prophylaxis, highlighting the potential benefit of early ferritin screen
Iberdomide-Based Oral Triple Therapy Extends Progression-Free Survival to 17.6 Months in Relapsed Multiple Myeloma: Results from the ICON Study
The phase 2 ICON trial reveals that iberdomide combined with low-dose cyclophosphamide and dexamethasone (IberCd) achieves a median PFS of 17.6 months in lenalidomide-refractory multiple myeloma. This all-oral regimen represents a significa
Engineering a Cure: How CAR T-Cell Therapy is Transforming the Fight Against Autoimmune Hemolytic Anemia
A groundbreaking study shows that CD19 CAR T-cell therapy can induce sustained, drug-free remission in patients with severe, multirefractory autoimmune hemolytic anemia by successfully eliminating the autoreactive B-cells that drive the dis
Tafasitamab Plus R2 Regimen Sets a New Benchmark for Relapsed or Refractory Follicular Lymphoma: Insights from the inMIND Trial
The Phase 3 inMIND trial demonstrates that adding tafasitamab to lenalidomide and rituximab (R2) significantly improves progression-free survival in patients with relapsed or refractory follicular lymphoma, reducing the risk of disease prog
Epcoritamab Plus R2 Redefines the Standard of Care in Relapsed or Refractory Follicular Lymphoma: Insights from the EPCORE FL-1 Trial
The Phase 3 EPCORE FL-1 trial demonstrates that adding epcoritamab to lenalidomide and rituximab (R2) significantly improves progression-free survival (HR 0.21) and response rates in relapsed/refractory follicular lymphoma, establishing a p
Model-Based ATG Dosing Successfully Accelerates CD4+ Reconstitution in CD34+ Selected Allogeneic HCT
A Phase 2 study demonstrates that pharmacokinetic model-based ATG dosing significantly enhances CD4+ T-cell reconstitution in patients undergoing CD34+ selected hematopoietic cell transplantation, reaching primary endpoints in 70% of partic
Venetoclax plus Azacitidine Emerges as a Potent Salvage Therapy for Relapsed or Refractory T-cell Acute Lymphoblastic Leukaemia
A multicentre phase 2 trial demonstrates that the combination of venetoclax and azacitidine achieves a 76% overall response rate in relapsed or refractory T-ALL, offering a manageable and effective alternative for a patient population with
Factor XI Inhibition Redefined: Catalytic Domain Blockade Emerges as a Superior Strategy for VTE Prevention
The ROXI-VTE trials demonstrate that inhibiting the Factor XI catalytic domain significantly reduces postoperative VTE compared to enoxaparin. While blocking Factor XIIa-mediated activation showed promise, it failed to meet superiority, hig
Clinical Evolution of Axicabtagene Ciloleucel: From Salvage Therapy to Second-Line Standard of Care
This review synthesizes clinical trial evidence for Axicabtagene Ciloleucel, tracing its development from refractory B-cell lymphoma to its current role as a second-line standard and its expansion into indolent and mantle cell lymphomas.
Adding Megestrol to Letrozole Enhances Antiproliferative Effects in ER+ Breast Cancer: Insights from the PIONEER Trial
The Phase 2b PIONEER trial reveals that adding megestrol to letrozole significantly reduces tumor proliferation in early-stage ER+ breast cancer. By reprogramming estrogen receptor activity, this combination offers a dual benefit of enhance
Music Therapy Proves Noninferior to Cognitive Behavioral Therapy for Managing Anxiety in Cancer Survivors: Results from a Randomized Trial
A randomized clinical trial demonstrates that telehealth-delivered music therapy is noninferior to cognitive behavioral therapy for reducing anxiety in cancer survivors, providing durable, clinically meaningful improvements and a viable alt
Inflammatory and Cardiac Biomarkers Predict VTE and Bleeding Risks in Ambulatory Cancer Patients
A post hoc analysis of the AVERT trial identifies GDF-15, NT-proBNP, CRP, and hs-TnT as significant predictors for venous thromboembolism and bleeding in cancer patients, offering new tools for personalized risk stratification.
High Efficacy of Pemigatinib in Myeloid/Lymphoid Neoplasms with FGFR1 Rearrangement: Insights from the FIGHT-203 Trial
The FIGHT-203 phase 2 trial demonstrates that pemigatinib, a selective FGFR inhibitor, induces high rates of complete clinical and cytogenetic responses in patients with FGFR1-rearranged myeloid/lymphoid neoplasms, offering a potent targete
Hepatitis C Eradication with Direct-Acting Antivirals: A Paradigm Shift in the Treatment of Indolent B-Cell Lymphomas
Long-term data from the BArT study and prospective observational trials demonstrate that direct-acting antivirals (DAAs) can achieve 100% viral clearance and durable hematologic responses in HCV-associated indolent lymphomas, potentially re
Beyond a Symptom: Baseline Fatigue as a Clinical Biomarker for Severe and Fatal Cancer Treatment Toxicities
A large-scale pooled analysis of 17 SWOG trials demonstrates that baseline patient-reported fatigue significantly increases the risk of severe, life-threatening, and fatal toxic effects from systemic cancer therapy, highlighting its role as
Scaling Symptom Relief: EHR-Facilitated Collaborative Care Outperforms Surveillance Alone in Large-Scale Oncology Trial
The E2C2 trial demonstrates that integrating electronic health record (EHR)-facilitated collaborative care with symptom surveillance significantly reduces the burden of anxiety, depression, and fatigue in oncology patients compared to surve
Breaking the Data Silos: Why Sharing Clinical Trial Biospecimens Is Non-Negotiable for Cancer Care
A critical review of 29 breast cancer registrational trials reveals a significant gap in biomarker research dissemination, prompting a call for mandatory data and biospecimen sharing to accelerate personalized oncology and honor patient con
Addressing the Silent Crisis: Menstrual Pain and Abnormal Bleeding as Drivers of Acute Care in Sickle Cell Disease
A multicenter study reveals that menstrual pain and abnormal uterine bleeding are highly prevalent in women with sickle cell disease and are linked to increased hospitalizations. Low awareness of hormonal therapies highlights a critical gap
Standardizing the Digital Signal: How an Ontology of Early Warning Signs Can Predict Cytokine Release Syndrome
This article explores a landmark mixed-methods study establishing a digital biomarker ontology for the early detection of Cytokine Release Syndrome (CRS). By identifying core physiological markers, researchers aim to transform immunotherapy
Browse by specialty
Open language-specific specialty feeds and department pages.